FDA approval of semaglutide (Wegovy) injection 2.4 mg for chronic weight management in adults with obesity or overweight

Approval of this once-weekly GLP-1 analogue based on phase III STEP programme (n=4,500). The STEP 1 trial showed that at 68 weeks, pts treated with semaglutide achieved more weight loss (14.9% vs. 2.4%) and achieved 5% or more body weight reduction (83.5% vs. 31.1%) vs placebo.

Source:

Biospace Inc.